Form 8-K - Current report:
SEC Accession No. 0001104659-24-126550
Filing Date
2024-12-09
Accepted
2024-12-09 08:35:20
Documents
13
Period of Report
2024-12-07
Items
Item 2.05: Cost Associated with Exit or Disposal Activities
Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
Item 8.01: Other Events

Document Format Files

Seq Description Document Type Size
1 FORM 8-K tm2430483d1_8k.htm   iXBRL 8-K 32127
  Complete submission text file 0001104659-24-126550.txt   208398

Data Files

Seq Description Document Type Size
2 XBRL TAXONOMY EXTENSION SCHEMA carm-20241207.xsd EX-101.SCH 3018
3 XBRL TAXONOMY EXTENSION LABEL LINKBASE carm-20241207_lab.xml EX-101.LAB 34240
4 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE carm-20241207_pre.xml EX-101.PRE 22361
15 EXTRACTED XBRL INSTANCE DOCUMENT tm2430483d1_8k_htm.xml XML 3684
Mailing Address 3675 MARKET STREET SUITE 200 PHILADELPHIA PA 19104
Business Address 3675 MARKET STREET SUITE 200 PHILADELPHIA PA 19104 2674916422
Carisma Therapeutics Inc. (Filer) CIK: 0001485003 (see all company filings)

EIN.: 262025616 | State of Incorp.: PA | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-36296 | Film No.: 241533950
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)